Navigation Links
iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
Date:8/6/2008

California venture will use personalized stem cell technology to battle

disease

MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire/ -- iZumi Bio, Inc., announced today that John T. Dimos, Ph.D., first author of the landmark Science paper "Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons," will join its team of scientists translating induced pluripotent stem (iPS) cell research into patient benefits. Dimos' work demonstrates the potential for iPS-derived cells in regenerative medicine.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080806/AQW065LOGO)

iPS cells are "reprogrammed" adult cells that have similar applications and potential to those of human embryonic stem (ES) cells, yet do not raise the same ethical concerns and can be generated in a patient-specific manner to maintain the disease-causing genetic profile while avoiding immune rejection.

Dimos' Science publication (online 31 July 2008; 10.1126/science.1158799) demonstrates that iPS cells derived from an individual patient can be differentiated into motor neurons, the cell type affected in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Large-scale, standardized production of such iPS-derived cells could be used for a variety of applications including models for drug discovery and cell-based therapies. Dimos conducted his work as a postdoctoral fellow in Kevin Eggan's lab at the Harvard Stem Cell Institute (http://www.hsci.harvard.edu). He earned his Ph.D. in Molecular Biology at Princeton University in Ihor Lemischka's laboratory, where he studied what defines a stem cell at the gene expression level.

"We are delighted that John has chosen iZumi to develop his groundbreaking research into practical regenerative medicine applications," said Thane Kreiner, Ph.D., President and CEO of iZumi. "We are committed to working with the most talented scientists worldwide to ensure that the enabling iPS technology benefits patients."

"There is broad interest in translating this basic research into discovery paradigms aimed at patient benefits," said Dimos. "iZumi has all the elements in place to successfully lead this translation including first-class investors, scientific leaders and collaborators; an experienced management team; and a passion for improving human health. I am honored to join the team."

About iZumi

iZumi Bio, Inc. was founded in 2007 and is funded by Kleiner Perkins Caufield and Byers and Highland Capital Partners. iZumi is using the power of induced pluripotent stem cells (iPS) to transform drug discovery and regenerative medicine. In June, 2008, iZumi announced a broad regenerative medicine and cardiovascular disease partnership with The Gladstone Institutes. The name iZumi, which means "fountain of youth," was chosen to honor the Japanese origins of iPS technology. iZumi is located in Mountain View, California.


'/>"/>
SOURCE iZumi Bio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
2. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
3. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
4. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
5. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
6. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
7. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
8. K-State Research Leading to Software to Help Nations Cattle Producers Identify Biosecurity Risks, Evaluate Impact of Cow-Calf Diseases Online
9. Leading Biotechnology Company Grows with StayinFront CRM
10. Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):